DIA: Driving Insights to Action
Science:Life Sciences
FDA has approved 11 biosimilars, but 41 biosimilars have been approved for use in Europe. The DIA 2018 Global Annual Meeting session “Interchangeable Biosimilars: A Global Perspective” explored the circumstances behind this difference and ways and reasons to close this gap, led by Session Chair Nielsen Hobbs (Executive Editor, US Policy & Regulatory, The Pink Sheet/Scrip), who was interviewed by DIA Senior Digital Copy Editor Chris Slawecki for this podcast. Watch the video of this podcast interview.
Califf: Digitization Will Return Humanity to Medicine
New Sources Changing the Meaning of Evidence?
AI Research Can Optimize Clinical/Operational Effectiveness
Has Joining ICH Accelerated Innovation in China?
Pricing Pitfalls in Prescription Drug Advertising
MID-NET Among PMDA’s First Steps Into RWE
Regulatory Science 2019: Leading or Holding Back Innovation?
23andMe: Information Empowering Patient Action
The Patient’s Most Engaging Question: Why?
EUnetHTA: Post-Launch Critical for Comparative Data
HSA Harmonizing Culture and Science in Singapore
Promoting Patient-Centric Business: MedComm in Latin America
Separate but Equal: Regulatory & Pricing Assessments in EU
Genetics Leading Modern Revolution in Cancer Care
Automation No Substitute for Scientific Leadership
R2D2 & C-17 New Landmarks in Canada’s Collaborative Pathways
Advanced Therapies Moving Upon Combination Platforms
Challenges in Generic Drug Safety & Surveillance
Interview with a DIA 2018 Patient Scholar
Novel Approaches to PV Collaboration
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Unexplainable
Speaking of Psychology
Stuff To Blow Your Mind